SourcingLink.net Licenses an Immune-Cell Therapy in Oncology from Tulynode Biosciences, Inc.
January 22 2019 - 10:50PM
InvestorsHub NewsWire
San Francisco, CA -- January 22, 2019 -- InvestorsHub
NewsWire -- SourcingLink.net (OTC PINK: SNET) has entered into
a licensing agreement with Tulynode Biosciences, Inc. of San Diego,
CA. Tulynode’s mission is to develop autologous immune-cell
therapy for durable clinical response. Tulynode has developed an
approach underlying the extracorporeal (situated outside the body)
immune-oncology cell therapy, a Immuno-Pod device. The device
will be used as a therapeutic that is hooked up in a “closed
circuit” with a patient’s vascular system.
This is a four-year licensing agreement with certain terms and
conditions that must be met. Tulynode grants SourcingLink.net
an exclusive, non-transferrable, non-sublicensable worldwide
license to the licensed technology in the following field of use:
extracorporeal medical device to generate immune cell engagement
(stimulation or suppression) to deliver seamless autologous immune
cell therapy and extracorporeal medical device for diagnostic
applications with technologies including but not limited to
immune-phenotyping and pathway profiling.
Additional information may be found on the Company’s
website: www.sourcinglink.net.
Along with the licensing agreement, SourcingLink.net has added a
Scientific Advisory Board (SAB) that will assist and advise the
executive management of the Company on scientific, business, legal
and regulatory matters in connection with the Company pursuing
further oncology therapy opportunities.
Dr. Mahant (a SAB member) stated: “that the autologous
immune-cell therapy approach pioneered by Tulynode is potentially a
powerful “tool” that may be used as a monotherapy and/or in synergy
with other therapies such as chemos.”
In addition to oncology, SourcingLink.net, Inc. has maintained
its 8 lithium-tantalum mining claims in James Bay, Quebec,
Canada. These assets remain part of SNET’s portfolio and may
be utilized for further mining and exploration in the future.
Moving forward, all funds raised by the company will be directed
towards oncology. Any funds directed towards mining expect to
be derived from revenues collected by the Company.
Forward-looking Statements:
This release contains “forward-looking statements” within the
meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements, which contain words such as
“expect”, “believe” or “plan”, by their nature address matters that
are, to different degrees, uncertain. These uncertainties may
cause actual future events to be materially different than those
expressed in our forward-looking statements. We do not
undertake to update our forward-looking statements.
One Sansome Street, Suite 3500
San Francisco, CA 94104
Phone 415-869-1038 Fax: 415.946.8801
Website: www.sourcinglink.net